AEterna Zentaris Partner Keryx Presents Phase 1 and Phase 2 Results for Anti-Cancer Compound Perifosine at ASCO Meeting



    Results showed an overall CBR of 52% which compares favorably with the
    activity of mTOR inhibitors

    QUEBEC CITY, QC, June 4 /CNW Telbec/ - AEterna Zentaris Inc. (TSX: AEZ;
NASDAQ:   AEZS), a global biopharmaceutical company focused on endocrine therapy
and oncology, today announced that its partner, Keryx Biopharmaceuticals
(NASDAQ:   KERX) presented a poster outlining Phase 1 and Phase 2 results for
perifosine, an oral anti-cancer signal transduction inhibitor compound, for
the treatment of patients with advanced sarcoma. Results of the Phase 1 and
Phase 2 studies of perifosine showed an overall clinical benefit rate (CBR) of
52% which compares favorably with the activity of mTOR inhibitors. The poster
titled, "Perifosine (P) an active agent in the treatment of patients with
advanced sarcoma": R. Birch, S. Chawla, J. Nemunaitis, P. Savage, P. Kaiser,
A. Spira, A. Cervera, E. Middleman, E. Sausville, M. Knowling, I. Henderson,
was presented Sunday, June 3, 2007 at the American Society of Clinical
Oncology's (ASCO) Annual Meeting currently being held in Chicago, Illinois.
    David J. Mazzo, Ph.D., President and CEO of AEterna Zentaris commented,
"We are very encouraged by the data from these Phase 1 and Phase 2 trials
confirming single agent activity with perifosine in patients with advanced
sarcomas, comparable to the activity of mTOR inhibitors."

    Background

    Perifosine is a novel oral alkylphospholipid that targets the PI3K
pathway upstream from mTOR by inhibiting the phosphorylation of Akt.
Perifosine's activity against sarcomas has now been evaluated in 145 patients
enrolled in one of three Phase 1 trials or four Phase 2 trials. Five of these
trials have been published.

    Methods

    Dose categories were as follows:

    
    -------------------------------------------------------------------------
    Lower Dose                           Higher Dose
    -------------------------------------------------------------------------
    Weekly 900 mg or less                Weekly 1200 mg or 1500 mg
    -------------------------------------------------------------------------
    Loading Dose 900 mg or less          Loading Dose 1200 mg or more
    -------------------------------------------------------------------------
    Daily Dose 100 mg or less            Daily Dose 150 mg or more
    -------------------------------------------------------------------------


    The dose schedules in the Phase 1 trials were weekly 100-800 mg or loading
dose (LD) 300-1800 mg on Day 1 followed by 50-150 mg daily for Days 2-21 every
28 days or LD 400-900 mg & daily 50-100 mg continuously.
    In the Phase 2 trials, doses were LD 900 mg Day 1 & 150 mg daily for days
2-21 every 28 days; LD 900 mg and 100 mg daily continuously; 50 mg daily
continuously without a LD; and 900-1500 mg weekly. LD was reduced for cycle 2+
of the 28 day regimens.

    Results

    145 patients with sarcoma were entered on studies prior to December 31,
2006 and were assessed for CBR. Partial responses were seen, in one patient
each, with chondrosarcoma, extra-skeletal myxoid chondrosarcoma,
leiomyosarcoma and a desmoid tumor.
    At lower doses with 52 patients fully evaluable for CBR, the CBR was 52%
with 4 partial responses and 23 stable disease at (greater than or equal to) 4
months.
    At higher doses with 30 patients fully evaluable for CBR, the CBR was 53%
with 16 stable disease at (greater than or equal to) 4 months.
    Toxicities were mainly gastrointestinal and/or fatigue. The percentage of
patients with grade 0 nausea (N), vomiting (V), diarrhea (D) and fatigue (F)
for lower dose perifosine (76 patients) was 46, 49, 38 and 55% respectively
compared to 26, 32, 20 and 58 percent for higher dose perifosine (69
patients). The proportion of patients with grade 2+ N, V, D and F was 20, 13,
15 and 21% for lower dose perifosine and 49, 35, 42 and 25% for higher dose
perifosine.

    Conclusions

    - Perifosine attained an overall 52% CBR which compares favorably with
      the activity of mTOR inhibitors;
    - Low dose perifosine (daily and weekly) achieved the same CBR as high
      dose, including four partial responses;
    - Toxicities were mainly gastrointestinal and/or fatigue. Low dose
      perifosine led to substantially less toxicity and decreased early
      withdrawal from therapy compared to high dose perifosine.
    

    A multi-center Phase 2 trial of low-dose perifosine in sarcomas that
generally do not respond to chemotherapy, including chondrosarcoma and myxoid
chondrosarcoma, is currently underway through the Sarcoma Alliance for
Research through Collaboration (SARC) network.

    About Perifosine (KRX-0401)

    Perifosine is a novel, first-in-class, oral anti-cancer agent that
modulates several key signal transduction pathways, including Akt, MAPK, and
JNK that have been shown to be critical for the survival of cancer cells.
Perifosine has demonstrated single agent anti-tumor activity in Phase 1 and
Phase 2 studies and is currently being studied as a single agent and in
combination with several forms of anti-cancer treatments for various forms of
cancer. Perifosine (KRX-0401) is licensed to Keryx Biopharmaceuticals in the
United States, Canada and Mexico.

    About AEterna Zentaris Inc.

    AEterna Zentaris Inc. is a global biopharmaceutical company focused on
endocrine therapy and oncology with proven expertise in drug discovery,
development and commercialization. News releases and additional information
are available at www.aeternazentaris.com.

    Forward-Looking Statements

    This press release contains forward-looking statements made pursuant to
the safe harbor provisions of the U.S. Securities Litigation Reform Act of
1995. Statements that are not historical facts, including statements preceded
by, followed by, or that include the words "believes", "anticipates",
"intends", "plans", "expects", "estimates", "will," "may", "should",
"approximately", and the negative or other variations of those terms or
comparable terminology, are forward-looking statements. Such statements
reflect management's current views, intentions, strategies and plans and are
based on certain assumptions.
    Forward-looking statements involve known and unknown risks and
uncertainties, which could cause the Company's actual results to differ
materially from those in the forward-looking statements. Such risks and
uncertainties include, among others, the ability of AEterna Zentaris to
implement its business strategies, the availability of funds and resources to
pursue R&D projects, the successful and timely completion of clinical studies,
the ability of AEterna Zentaris to take advantage of business opportunities in
the pharmaceutical industry, uncertainties related to the regulatory process
and general changes in economic conditions. Investors should consult the
Company's quarterly and annual filings with the Canadian and U.S. securities
commissions for additional information on risks and uncertainties relating to
the forward-looking statements. Investors are cautioned not to rely on these
forward-looking statements. The Company does not undertake to update these
forward-looking statements.




For further information:

For further information: Jenene Thomas, Senior Director, Investor
Relations & Corporate Communications, (908) 938-1475,
jenene.thomas@aeternazentaris.com; Paul Burroughs, Media Relations, (418)
652-8525, ext. 406, paul.burroughs@aeternazentaris.com

Organization Profile

Aeterna Zentaris Inc.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890